News: Calzada starts treatment of first patient with a major burn injury

Calzada (ASX:CZD) has implanted its Biodegradable Temporising Matrix into its first patient in its clinical trial with a major burn injury.

The matrix, a NovoSorb device designed to repair full thickness burn wounds, will be assessed for integration in the wound, the ease of removal of the seal prior to skin grafting and the minimisation of contraction and scarring.

This patient sustained flame burns to 75% of his total body surface area with full thickness burns affecting 45% of this area.

Calzada noted that the patient’s treatment, including the use of the BTM, has progressed as planned.

The study commenced recruitment on 1 January 2014 although recruitment has been slow as few burns victims have met the study inclusion criteria.

Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.